European consensus on diagnosis and treatment of germ cell cancer

A report of the European Germ Cell Cancer Consensus Group (EGCCCG)

Hans Joachim Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, J. P. Droz, G. Pizzocaro, G. Daugaard, P. H M de Mulder, A. Horwich, T. Oliver, R. Huddart, G. Rosti, L. Paz Ares, O. Pont & 48 others J. T. Hartmann, N. Aass, F. Algaba, M. Bamberg, I. Bodrogi, C. Bokemeyer, J. Classen, S. Clemm, S. Culine, M. de Wit, H. G. Derigs, K. P. Dieckmann, M. Flasshove, X. Garcia del Muro, A. Gerl, J. R. German-Lluch, M. Hartmann, A. Heidenreich, W. Hoeltl, J. Joffe, W. Jones, G. Kaiser, O. Klepp, S. Kliesch, L. Kisbenedek, K. U. Koehrmann, M. Kuczyk, M. P. Laguna, O. Leiva, V. Loy, M. D. Mason, G. M. Mead, R. P. Mueller, N. Nicolai, G. O N Oosterhof, T. Pottek, O. Rick, H. Schmidberger, F. Sedlmayer, W. Siegert, U. Studer, S. Tjulandin, H. von der Maase, P. Walz, S. Weinknecht, L. Weissbach, E. Winter, C. Wittekind

Research output: Contribution to journalArticle

365 Citations (Scopus)

Abstract

Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of ≥99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception.

Original languageEnglish
Pages (from-to)1377-1399
Number of pages23
JournalAnnals of Oncology
Volume15
Issue number9
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Germ Cell and Embryonal Neoplasms
Consensus
Therapeutics
Guidelines
Adjuvant Chemotherapy
Patient Compliance
Platinum
Blood Vessels
Dissection
Histology
Radiation
Physicians
Drug Therapy
Incidence

Keywords

  • Consensus on diagnosis and treatment
  • Germ cell tumour
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., ... Wittekind, C. (2004). European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Annals of Oncology, 15(9), 1377-1399. https://doi.org/10.1093/annonc/mdh301

European consensus on diagnosis and treatment of germ cell cancer : A report of the European Germ Cell Cancer Consensus Group (EGCCCG). / Schmoll, Hans Joachim; Souchon, R.; Krege, S.; Albers, P.; Beyer, J.; Kollmannsberger, C.; Fossa, S. D.; Skakkebaek, N. E.; de Wit, R.; Fizazi, K.; Droz, J. P.; Pizzocaro, G.; Daugaard, G.; de Mulder, P. H M; Horwich, A.; Oliver, T.; Huddart, R.; Rosti, G.; Paz Ares, L.; Pont, O.; Hartmann, J. T.; Aass, N.; Algaba, F.; Bamberg, M.; Bodrogi, I.; Bokemeyer, C.; Classen, J.; Clemm, S.; Culine, S.; de Wit, M.; Derigs, H. G.; Dieckmann, K. P.; Flasshove, M.; Garcia del Muro, X.; Gerl, A.; German-Lluch, J. R.; Hartmann, M.; Heidenreich, A.; Hoeltl, W.; Joffe, J.; Jones, W.; Kaiser, G.; Klepp, O.; Kliesch, S.; Kisbenedek, L.; Koehrmann, K. U.; Kuczyk, M.; Laguna, M. P.; Leiva, O.; Loy, V.; Mason, M. D.; Mead, G. M.; Mueller, R. P.; Nicolai, N.; Oosterhof, G. O N; Pottek, T.; Rick, O.; Schmidberger, H.; Sedlmayer, F.; Siegert, W.; Studer, U.; Tjulandin, S.; von der Maase, H.; Walz, P.; Weinknecht, S.; Weissbach, L.; Winter, E.; Wittekind, C.

In: Annals of Oncology, Vol. 15, No. 9, 09.2004, p. 1377-1399.

Research output: Contribution to journalArticle

Schmoll, HJ, Souchon, R, Krege, S, Albers, P, Beyer, J, Kollmannsberger, C, Fossa, SD, Skakkebaek, NE, de Wit, R, Fizazi, K, Droz, JP, Pizzocaro, G, Daugaard, G, de Mulder, PHM, Horwich, A, Oliver, T, Huddart, R, Rosti, G, Paz Ares, L, Pont, O, Hartmann, JT, Aass, N, Algaba, F, Bamberg, M, Bodrogi, I, Bokemeyer, C, Classen, J, Clemm, S, Culine, S, de Wit, M, Derigs, HG, Dieckmann, KP, Flasshove, M, Garcia del Muro, X, Gerl, A, German-Lluch, JR, Hartmann, M, Heidenreich, A, Hoeltl, W, Joffe, J, Jones, W, Kaiser, G, Klepp, O, Kliesch, S, Kisbenedek, L, Koehrmann, KU, Kuczyk, M, Laguna, MP, Leiva, O, Loy, V, Mason, MD, Mead, GM, Mueller, RP, Nicolai, N, Oosterhof, GON, Pottek, T, Rick, O, Schmidberger, H, Sedlmayer, F, Siegert, W, Studer, U, Tjulandin, S, von der Maase, H, Walz, P, Weinknecht, S, Weissbach, L, Winter, E & Wittekind, C 2004, 'European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG)', Annals of Oncology, vol. 15, no. 9, pp. 1377-1399. https://doi.org/10.1093/annonc/mdh301
Schmoll, Hans Joachim ; Souchon, R. ; Krege, S. ; Albers, P. ; Beyer, J. ; Kollmannsberger, C. ; Fossa, S. D. ; Skakkebaek, N. E. ; de Wit, R. ; Fizazi, K. ; Droz, J. P. ; Pizzocaro, G. ; Daugaard, G. ; de Mulder, P. H M ; Horwich, A. ; Oliver, T. ; Huddart, R. ; Rosti, G. ; Paz Ares, L. ; Pont, O. ; Hartmann, J. T. ; Aass, N. ; Algaba, F. ; Bamberg, M. ; Bodrogi, I. ; Bokemeyer, C. ; Classen, J. ; Clemm, S. ; Culine, S. ; de Wit, M. ; Derigs, H. G. ; Dieckmann, K. P. ; Flasshove, M. ; Garcia del Muro, X. ; Gerl, A. ; German-Lluch, J. R. ; Hartmann, M. ; Heidenreich, A. ; Hoeltl, W. ; Joffe, J. ; Jones, W. ; Kaiser, G. ; Klepp, O. ; Kliesch, S. ; Kisbenedek, L. ; Koehrmann, K. U. ; Kuczyk, M. ; Laguna, M. P. ; Leiva, O. ; Loy, V. ; Mason, M. D. ; Mead, G. M. ; Mueller, R. P. ; Nicolai, N. ; Oosterhof, G. O N ; Pottek, T. ; Rick, O. ; Schmidberger, H. ; Sedlmayer, F. ; Siegert, W. ; Studer, U. ; Tjulandin, S. ; von der Maase, H. ; Walz, P. ; Weinknecht, S. ; Weissbach, L. ; Winter, E. ; Wittekind, C. / European consensus on diagnosis and treatment of germ cell cancer : A report of the European Germ Cell Cancer Consensus Group (EGCCCG). In: Annals of Oncology. 2004 ; Vol. 15, No. 9. pp. 1377-1399.
@article{6af97ed3ff304bd3b026865809c395b9,
title = "European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG)",
abstract = "Germ cell tumour is the most frequent malignant tumour type in young men with a 100{\%} rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of ≥99{\%} in early stages and 90{\%}, 75-80{\%} and 50{\%} in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception.",
keywords = "Consensus on diagnosis and treatment, Germ cell tumour, Testicular cancer",
author = "Schmoll, {Hans Joachim} and R. Souchon and S. Krege and P. Albers and J. Beyer and C. Kollmannsberger and Fossa, {S. D.} and Skakkebaek, {N. E.} and {de Wit}, R. and K. Fizazi and Droz, {J. P.} and G. Pizzocaro and G. Daugaard and {de Mulder}, {P. H M} and A. Horwich and T. Oliver and R. Huddart and G. Rosti and {Paz Ares}, L. and O. Pont and Hartmann, {J. T.} and N. Aass and F. Algaba and M. Bamberg and I. Bodrogi and C. Bokemeyer and J. Classen and S. Clemm and S. Culine and {de Wit}, M. and Derigs, {H. G.} and Dieckmann, {K. P.} and M. Flasshove and {Garcia del Muro}, X. and A. Gerl and German-Lluch, {J. R.} and M. Hartmann and A. Heidenreich and W. Hoeltl and J. Joffe and W. Jones and G. Kaiser and O. Klepp and S. Kliesch and L. Kisbenedek and Koehrmann, {K. U.} and M. Kuczyk and Laguna, {M. P.} and O. Leiva and V. Loy and Mason, {M. D.} and Mead, {G. M.} and Mueller, {R. P.} and N. Nicolai and Oosterhof, {G. O N} and T. Pottek and O. Rick and H. Schmidberger and F. Sedlmayer and W. Siegert and U. Studer and S. Tjulandin and {von der Maase}, H. and P. Walz and S. Weinknecht and L. Weissbach and E. Winter and C. Wittekind",
year = "2004",
month = "9",
doi = "10.1093/annonc/mdh301",
language = "English",
volume = "15",
pages = "1377--1399",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - European consensus on diagnosis and treatment of germ cell cancer

T2 - A report of the European Germ Cell Cancer Consensus Group (EGCCCG)

AU - Schmoll, Hans Joachim

AU - Souchon, R.

AU - Krege, S.

AU - Albers, P.

AU - Beyer, J.

AU - Kollmannsberger, C.

AU - Fossa, S. D.

AU - Skakkebaek, N. E.

AU - de Wit, R.

AU - Fizazi, K.

AU - Droz, J. P.

AU - Pizzocaro, G.

AU - Daugaard, G.

AU - de Mulder, P. H M

AU - Horwich, A.

AU - Oliver, T.

AU - Huddart, R.

AU - Rosti, G.

AU - Paz Ares, L.

AU - Pont, O.

AU - Hartmann, J. T.

AU - Aass, N.

AU - Algaba, F.

AU - Bamberg, M.

AU - Bodrogi, I.

AU - Bokemeyer, C.

AU - Classen, J.

AU - Clemm, S.

AU - Culine, S.

AU - de Wit, M.

AU - Derigs, H. G.

AU - Dieckmann, K. P.

AU - Flasshove, M.

AU - Garcia del Muro, X.

AU - Gerl, A.

AU - German-Lluch, J. R.

AU - Hartmann, M.

AU - Heidenreich, A.

AU - Hoeltl, W.

AU - Joffe, J.

AU - Jones, W.

AU - Kaiser, G.

AU - Klepp, O.

AU - Kliesch, S.

AU - Kisbenedek, L.

AU - Koehrmann, K. U.

AU - Kuczyk, M.

AU - Laguna, M. P.

AU - Leiva, O.

AU - Loy, V.

AU - Mason, M. D.

AU - Mead, G. M.

AU - Mueller, R. P.

AU - Nicolai, N.

AU - Oosterhof, G. O N

AU - Pottek, T.

AU - Rick, O.

AU - Schmidberger, H.

AU - Sedlmayer, F.

AU - Siegert, W.

AU - Studer, U.

AU - Tjulandin, S.

AU - von der Maase, H.

AU - Walz, P.

AU - Weinknecht, S.

AU - Weissbach, L.

AU - Winter, E.

AU - Wittekind, C.

PY - 2004/9

Y1 - 2004/9

N2 - Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of ≥99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception.

AB - Germ cell tumour is the most frequent malignant tumour type in young men with a 100% rise in the incidence every 20 years. Despite this, the high sensitivity of germ cell tumours to platinum-based chemotherapy, together with radiation and surgical measures, leads to the high cure rate of ≥99% in early stages and 90%, 75-80% and 50% in advanced disease with 'good', 'intermediate' and 'poor' prognostic criteria (IGCCCG classification), respectively. The high cure rate in patients with limited metastatic disease allows the reduction of overall treatment load, and therefore less acute and long-term toxicity, e.g. organ sparing surgery for specific cases, reduced dose and treatment volume of irradiation or substitution of node dissection by surveillance or adjuvant chemotherapy according to the presence or absence of vascular invasion. Thus, different treatment options according to prognostic factors including histology, stage and patient factors and possibilities of the treating centre as well may be used to define the treatment strategy which is definitively chosen for an individual patient. However, this strategy of reduction of treatment load as well as the treatment itself require very high expertise of the treating physician with careful management and follow-up and thorough cooperation by the patient as well to maintain the high rate for cure. Treatment decisions must be based on the available evidence which has been the basis for this consensus guideline delivering a clear proposal for diagnostic and treatment measures in each stage of gonadal and extragonadal germ cell tumour and individual clinical situations. Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception.

KW - Consensus on diagnosis and treatment

KW - Germ cell tumour

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=4644330119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644330119&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh301

DO - 10.1093/annonc/mdh301

M3 - Article

VL - 15

SP - 1377

EP - 1399

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -